Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice
J. Clin. Invest. Juliana Hamzah, et al. 118:1691 doi:10.1172/JCI33201 [Go to this article.]

Figure 2
Therapeutic efficacy of intratumoral anti-CD40/IL-2 treatment. (A) Schematic representation of treatment regimen for 23-week-old RIP1-Tag5 mice treated for 10 weeks. Survival was monitored up to 45 weeks. (B) Kaplan-Meier survival curve of RIP1-Tag5 mice treated with anti-rat IgG/RGR peptide as control and a combination of anti-CD40 and IL-2 without RGR peptide. (C) Survival curve of RIP1-Tag5 mice treated with anti-CD40–RGR antibodies, IL-2–RGR fusion proteins, and a combination of anti-CD40–RGR/IL-2–RGR (n = 8–10). One out of 2 experiments is shown.